SUPPLEMENTAL MATERIAL

Table S1. Association between serum FGF21 levels and clinical parameters.

	n	FGF21 level, pg/ml	P value
Ever smoker			0.119
yes	137	233.9 (113.3-405.5)	-
no	234	227.4 (122.2-407.8)	-
Dyslipidemia			<0.001
yes	215	303.1 (154.1-459.7)	-
no	156	168.2 (93.1-295.5)	-
Hypertension			0.017
yes	153	268.0 (136.0-440.3)	-
no	218	208.9 (107.4-374.2)	-

Data are presented as median (interquartile range).

FGF21, fibroblast growth factor 21.

Table S2. Absolute difference related to the increase of one standard deviation of FGF21 level.

Variables	B (95% CI)	P Value
Waist circumference	0.001 (-0.015, 0.016)	0.918
C-IMT	-0.063 (-0.679, 0.552)	0.840
SBP	-0.001 (-0.008, 0.006)	0.744
DBP	-0.002 (-0.014, 0.011)	0.778
FBG	-0.014 (-0.051, 0.023)	0.459
2hBG	-0.004 (-0.026, 0.017)	0.702
Fasting insulin	-0.004 (-0.012, 0.003)	0.272
HOMA-IR	-0.007 (-0.025, 0.010)	0.422
Triglycerides	**0.477 (0.336, 0.617)**	**<0.001**
Total cholesterol	0.072 (-0.023, 0.168)	0.135
HDL-C	**-0.650 (-0.976, -0.324)**	**<0.001**
LDL-C	0.080 (-0.033, 0.193)	0.166
hsCRP	-0.003 (-0.012, 0.006)	0.520

Regression coefficient (B): absolute changes in the variables associated with one standard deviation increase in ln-transformed FGF21 level.

Adjusted for age and BMI.

2hBG, 2-hour blood glucose; BMI, body mass index; C-IMT, carotid intima-media thickness; DBP, diastolic blood pressure; FGF21, fibroblast growth factor 21; HDL-C, high-density lipoproteins cholesterol; HOMA-IR, homeostatic model assessment for insulin resistance index; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.

Table S3. Absolute difference related to the increase of one standard deviation of FGF21 level at baseline.

Variables	B (95%CI)	P Value
Waist circumference	0.010 (-0.003, 0.023)	0.122
SBP	0.004 (0.000, 0.009)	0.053
DBP	0.006 (-0.002, 0.014)	0.128
FBG	0.000 (-0.049, 0.049)	0.990
2hBG	0.035 (0.005, 0.065)	0.024
HOMA-IR	0.038 (-0.04, 0.115)	0.341
HbA1c	0.046 (-0.026, 0.118)	0.211
Triglycerides	**0.116 (0.071, 0.162)**	**<0.001**
Total cholesterol	0.059 (-0.017, 0.135)	0.128
HDL-C	**-0.532 (-0.739, -0.325)**	**<0.001**
LDL-C	0.001 (-0.09, 0.092)	0.986
eGFR	-0.002 (-0.005, 0.001)	0.262
hsCRP	0.004 (-0.032, 0.039)	0.836
Lipocalin-2	0.005 (-0.002, 0.012)	0.196

Regression coefficient (B): absolute change in the variables associated with one standard deviation increase in ln-transformed FGF21 level.

Adjusted for age and BMI.

2hBG, 2-hour blood glucose; BMI, body mass index; C-IMT, carotid intima-media thickness; DBP, diastolic blood pressure; FGF21, fibroblast growth factor 21; HDL-C, high-density lipoproteins cholesterol; HOMA-IR, homeostatic model assessment for insulin resistance index; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.

Figure S1. Flow chart of the prospective study population.

ASCVD, atherosclerotic cardiovascular disease. CVD, cardiovascular disease.